"RNA, Messenger" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
| Descriptor ID |
D012333
|
| MeSH Number(s) |
D13.444.735.544
|
| Concept/Terms |
mRNA, Polyadenylated- mRNA, Polyadenylated
- RNA, Messenger, Polyadenylated
- Messenger RNA, Polyadenylated
- Polyadenylated Messenger RNA
- RNA, Polyadenylated Messenger
- Polyadenylated mRNA
- Poly(A)+ mRNA
|
Below are MeSH descriptors whose meaning is more general than "RNA, Messenger".
Below are MeSH descriptors whose meaning is more specific than "RNA, Messenger".
This graph shows the total number of publications written about "RNA, Messenger" by people in this website by year, and whether "RNA, Messenger" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 10 | 10 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "RNA, Messenger" by people in Profiles.
-
Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders. Influenza Other Respir Viruses. 2024 Mar; 18(3):e13269.
-
Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system. Vaccine. 2023 Nov 30; 41(49):7460-7468.
-
Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study. JMIR Public Health Surveill. 2023 Oct 04; 9:e46318.
-
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 09 07; 41(39):5678-5682.
-
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
-
Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink. Pediatrics. 2023 Jul 01; 152(1).
-
Effects of high incubation temperature on tight junction proteins in the yolk sac and small intestine of embryonic broilers. Poult Sci. 2023 Sep; 102(9):102875.
-
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023 08 23; 41(37):5424-5434.
-
Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination. Obstet Gynecol. 2023 Jul 01; 142(1):125-129.
-
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.